Xilio Therapeutics, Inc. (XLO)
NASDAQ: XLO · Real-Time Price · USD
0.930
-0.130 (-12.26%)
At close: Feb 21, 2025, 4:00 PM
0.915
-0.015 (-1.61%)
After-hours: Feb 21, 2025, 7:59 PM EST
Xilio Therapeutics Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Xilio Therapeutics stock has a target of 4.00, which predicts an increase of 330.11% from the current stock price of 0.93.
Analyst Consensus: Buy
* Price targets were last updated on Nov 8, 2024.
Analyst Ratings
According to 1 stock analyst, the rating for Xilio Therapeutics is "Buy". This means that the analyst believes this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 0 | 0 | 0 | 0 |
| Buy | 2 | 2 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 1 | 1 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Raymond James | Raymond James | Buy Maintains $6 → $4 | Buy | Maintains | $6 → $4 | +330.11% | Nov 8, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +652.69% | May 30, 2023 |
| Chardan Capital | Chardan Capital | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +652.69% | May 11, 2023 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $20 → $10 | Buy | Maintains | $20 → $10 | +975.27% | Jan 27, 2023 |
| Chardan Capital | Chardan Capital | Strong Buy Initiates $7 | Strong Buy | Initiates | $7 | +652.69% | Dec 21, 2022 |
Financial Forecast
Revenue This Year
7.78M
Revenue Next Year
51.24M
from 7.78M
Increased by 558.79%
EPS This Year
-1.15
from -2.78
EPS Next Year
-0.36
from -1.15
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 11.8M | 73.5M | 89.3M | |||
| Avg | 7.8M | 51.2M | 64.8M | |||
| Low | 4.9M | 22.7M | 31.9M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | 845.0% | 74.2% | |||
| Avg | - | 558.8% | 26.5% | |||
| Low | - | 192.3% | -37.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -1.10 | - | -0.45 |
| Avg | -1.15 | -0.36 | -0.49 |
| Low | -1.19 | -0.83 | -0.55 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.